Genital tract immune activation, inflammation and sexually transmitted infections in CAPRISA 008 trial participants. by Mhlungu, Sanele Nobleman.
 i 
 
Genital tract immune activation, inflammation 
and sexually transmitted infections in CAPRISA 
008 trial participants 
By 
Sanele Nobleman Mhlungu 
(Student number: 209504114) 
 
Submitted in fulfilment of requirements of the degree Master of 
Medical Science in Virology, School of Laboratory Medicine and 




Supervisor: Dr. LJ Liebenberg 
Co-supervisor: Dr S Ngcapu 
 ii 
PREFACE AND DECLARATION 
I, Mr. SN. Mhlungu, declare as follows:  
1. The work in this thesis has not been submitted to the University of KwaZulu-Natal 
(UKZN) or any other tertiary institution for purposes of obtaining an academic 
qualification, whether by myself or any other party.  
2. My contribution towards this project was as follows: handling of all the specimens, 
including processing based on the techniques as stipulated in the methodology sections 
and acquiring data. Also, analysis of data and the writing of this thesis. 
3. The contributions of others towards this project were as follows:  
Dr. Lenine J. Liebenberg: Supervisor 
Dr. Sinaye Ngcapu: Co-supervisor 
 
 




This master’s thesis is dedicated to my late mother Ntombizethu Anna Mhlungu. 
Though she has passed on, she remains forever an important part in my life. I will 
forever love her and cherish all the good times we had. This work is also dedicated to 




I would like to thank Dr L.J Liebenberg, she has been an awesome supervisor and 
mentor. I am thankful for all her support and guidance over the years. I would like to 
further thank Dr S. Ngcapu, as my co-supervisor for all the support and motivation. 
Both have played a major role in refining and shaping me as a young scientific 
researcher. All the skills I learned will be worthwhile in the future. I would also like to 
express thanks to the Centre for the AIDS Programme of Research in South Africa 
(CAPRISA) for hosting me as a fellow student and for providing the funding for this 




TABLE OF CONTENTS 
 
PREFACE AND DECLARATION .................................................................................... II 
DEDICATION ..................................................................................................................III 
ACKNOWLEDGEMENTS .............................................................................................. IV 
LIST OF FIGURES ......................................................................................................... VII 
LIST OF TABLES ......................................................................................................... VIII 
LIST OF ABBREVIATIONS ........................................................................................... IX 
ABSTRACT .................................................................................................................... XII 
CHAPTER 1: INTRODUCTION ....................................................................................... 1 
1.1 INTRODUCTION .................................................................................................................... 1 
1.2 STUDY AIM AND OBJECTIVE ................................................................................................ 4 
CHAPTER 2: LITERATURE REVIEW ............................................................................ 5 
2.1 HIV EPIDEMIC ...................................................................................................................... 5 
2.2 THE FEMALE GENITAL TRACT .............................................................................................. 6 
2.3 HIV-1 TRANSMISSION ACROSS THE FEMALE GENITAL TRACT ............................................. 8 
2.3.1 Mucosal immune system and HIV ................................................................................. 8 
2.4 GENITAL INFLAMMATION AND HIV RISK ............................................................................ 9 
2.5 GENITAL INFLAMMATION, IMMUNE ACTIVATION, HIV SHEDDING AND DISEASE 
PROGRESSION ........................................................................................................................... 10 
2.6 CONSEQUENCES OF SEXUALLY TRANSMITTED INFECTIONS IN THE FEMALE GENITAL 
TRACT ...................................................................................................................................... 11 
CHAPER 3. RESEARCH DESIGN AND METHODOLOGY .......................................... 13 
3.1. STUDY PARTICIPANTS ................................................................................................... 13 
3.1.1 HIV testing at screening and enrolment ................................................................ 13 
3.2 BIOLOGICAL SPECIMEN COLLECTION AND PROCESSING .............................................. 13 
3.2.1 Cervicovaginal Lavage .......................................................................................... 14 
3.2.2 Vulvovaginal Swab ................................................................................................ 14 
3.2.3  Cytobrushes ........................................................................................................... 14 
3.2.4 Cell counting using Trypan Blue Exclusion Method ............................................. 15 
3.3 INVESTIGATION OF CELLULAR ACTIVATION BY FLOW CYTOMETRY ............................. 15 
3.3.1 Surface staining of cellular immune markers ........................................................ 15 
3.3.2 Intracellular staining of cellular immune markers ................................................ 16 
3.3.4 Preparation of compensation beads ...................................................................... 17 
3.3.5 Data acquisition .................................................................................................... 18 
3.4 MEASUREMENT OF GENITAL TRACT CYTOKINE CONCENTRATIONS.............................. 18 
3.4.1. Multiplex ELISA plate preparation ....................................................................... 18 
3.4.2  The Multiplex ELISA Assay ................................................................................... 19 
3.4.2 Standard preparation ............................................................................................ 21 
3.4.3 Bead preparation ................................................................................................... 21 
3.4.4 Detection antibody preparation ............................................................................ 22 
 vi 
3.4.5 Streptavidin-PE preparation ................................................................................. 22 
3.5  STI TESTING .................................................................................................................. 22 
3.6  STATISTICAL ANALYSIS ................................................................................................ 22 
CHAPTER 4. RESULTS .................................................................................................. 23 
4.1 CLINICAL AND SOCIO-BEHAVIORAL CHARACTERISTICS OF THE STUDY PARTICIPANTS .... 23 
4.2 CELLULAR ACTIVATION AND INFLAMMATION IN CAPRISA 008 PARTICIPANTS. ........ 26 
4.3 SEXUALLY TRANSMITTED INFECTIONS AS POTENTIAL DRIVERS OF GENITAL IMMUNE 
ACTIVATION AND INFLAMMATION. .......................................................................................... 32 
CHAPTER 5: DISCUSSION AND CONCLUSION ......................................................... 36 
REFERENCES:..…………………………………………………..………………….46 
APPENDIX ...................................................................................................................... 45 
 
   
  
 vii 
LIST OF FIGURES 
Figure 1.1: The prevalence of HIV cases in adults and young children………………5 
Figure 1.2: The anatomical structure of the female genital tract……………………..7 
Figure 1.2: Global estimates of new cases of curable STIs: syphilis, trichomoniasis, 
chlamydia and gonorrhoeae………………………………………….…………...…12 
Figure 2.1:  Summary of the multiplex ELISA assay procedure…………………......20 
Figure 2.2: Preparation of multiplex ELISA assay…………………….…………..….21  
Figure 3.1: The distribution frequency of activated T cells defined by dual expression 
of CD38+ and HLA-DR+ on each patient and the comparison of genital immune T cells 
between women with high and low activation status…………………………………..27 
Figure 3.2: Representative diagram showing the cytokine/chemokine expression 
between women with high and low T cell immune activation status in the CD4+ T cell 
population………………………………………………………………………………30 
Figure 3.3: Representative diagram on the relationship between activated CD4+ T cell 









LIST OF TABLES 
Table 1. Representative diagram for plate design showing how standards, blanks, 
controls and CVLs were plated……………………………………………………….19  
Table 2A: Clinical and socio-behavioral characteristics in the 008 CAPRISA 
study………………………………………………………………………………….22 
Table 2B: Baseline immune activation status in the CD3+, CD4+ and CD8+ population 
from live lymphocytes in the genital mucosa in the CAPRISA 008 participants 
(n=120)……………………………………………………………………………..…..25 
Table 3: Prevalence of STIs between women with and without genital 
inflammation……............................................................................................................33 
Table 4: The association between the presence of STIs and T cell immune activation 
status……………………..………………………………….………………………….34 
























Acquire immune-deficiency syndrome 
Allophycocyanin tandem dye H-7 
Cervical mononuclear cells 
Cutaneous T cell-attracting chemokine 
Cervicovaginal lavage 
Chemokine receptor 5 
Cluster of differentiation 
Carcinoembryonic antigen-related cellular adhesion 
 molecule 
Enzyme immunoassay 
Female genital tract 
Fluorescein isothiocyanate  
Fluorescence minus one 
Foetal bovine serum 
Female sex workers 
Granulocyte colony stimulating factor 
Granulocyte macrophage colony stimulating factor 
Hepatocyte growth factor 






















Human immunodeficiency virus 
Interferon 
Interleukin 
Leukemia inhibitory factor 
Macrophage colony stimulating factor 
Monocyte chemoattractant protein 
Macrophage inhibitory factor 
Macrophage inflammatory protein 
Peripheral blood mononuclear cells 
Phosphate buffer saline 
Polymerase chain reaction. 
Platelet-derived growth factor beta polypepetide  
Phycoerythrin 
peridinin-chlorophyll protein-cyanine 5.5 
Red blood cells 
Roswell Park Memorial Park Institute Medium  
Stem cell factor 
Stem cell growth factor beta 
Stromal cell derived factor 1 alpha 






Sexually transmitted infection 
Tenofovir gel 
Tumour Necrosis Factor 




















Background: Data from the CAPRISA 004 trial demonstrated that women with 
elevated genital inflammatory cytokines have increased risk of HIV acquisition. Other 
biological factors known to impact HIV risk include, among others, sexually transmitted 
infections, and immune cell activation. The aim of this study was to determine whether 
immune cell activation and elevated frequencies of genital CD4+CCR5+ target cells for 
HIV infection are associated with (1) increased genital markers of inflammation; and (2) 
with the presence of sexually transmitted infections (STIs).  
 
Methods: Cervical cytobrushes and cervicovaginal fluids collected from HIV 
seronegative CAPRISA 008 participants (n=166) were used to measure genital T cell 
immune activation and inflammation respectively.  Flow cytometry was used to identify 
cellular targets for HIV infection (CD4+CCR5+), activated cells, and proliferating cells. 
Dual expression of CD38+/HLA-DR+ above 75th and below 25th percentile defined 
women with high and low immune T cell activation respectively. Genital inflammation 
was defined by elevated levels of at least 5 of any 9 key cytokines as previously 
described by (Masson et al., 2015). The presence of selected discharge-associated STIs 
(N. gonorrhoeae, C. trachomatis, T. vaginalis and M. genitalium) were determined by 
multiplexed PCR. 
 
Results: This study found that women with high immune activation had significantly 
higher frequencies of CD4+CCR5+ (p<0.0001) and proliferating CD4+CCR5+ 
(p<0.0001) T cells compared to women with low immune activation. The prevalence of 
C. trachomatis, T vaginalis or any combination of any STI (p=0.0034, p=0.0024 and 
p=0.0002 respectively) was significantly higher in women with genital inflammation 
(n=31) compared to those without inflammation (n=134). There was no statistically 
significant association between cellular markers of immune activation and 
inflammation. STI were observed more often in the women characterized by high levels 
of immune activation compared to women with low levels of immune activation. 
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Although this was not statistically significant, taken together this demonstrates a 
contribution by STI to immune activation at the genital tract. Furthermore, when the 
frequency of CD4+CCR5+ expressing cells was compared between women with STIs 
and those without STIs, women infected with C. trichomonas or any STI combination 
had significantly higher frequencies of CD4+CCR5+. Taken together, these data 
demonstrate a contribution by STI to immune activation and inflammation at the genital 
tract. 
 
Conclusion: While it has been well documented that the genital mucosa provides robust 
mechanisms that protect against pathogens, STIs play a significant role in the 
recruitment of HIV target cells, and are potential drivers of the inflammation in the 
genital tract that fosters an environment conducive to HIV acquisition. It is of great 
urgency that future biomedical interventions are made to curb HIV acquisition as a 
result of predisposition to STIs in women.
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
The female genital tract (FGT) is composed of specialized compartments which include: 
the lower part (vagina and ectocervix), the transitional endocervix and the upper part 
(endometrium and fallopian tubes) (Ochiel et al., 2008). In addition to the epithelial 
lining present at these compartments, the FGT contains mucus which serves as a 
protective barrier against invading pathogens (Ochiel et al., 2008). The FGT also has 
defensins, these are small proteins which possess a broad range of activities involved 
ranging from anti-microbial activity, inducing cell proliferation and modulate innate and 
acquired immunity (Bowdish et al., 2006). However despite all these active functions to 
protect itself against invading pathogens, it is considered a hostile environment in which 
multiple factors can influence the integrity of the genital mucosal epithelial barrier, 
rendering the female genital tract susceptible to colonization and  establishment of an 
infection (Machado et al., 2014).  
 
Multiple factors are known to influence this natural barrier against infection and an 
imbalance in mucosal regulation may potentially give way for  HIV to penetrate the 
barrier and initiate a productive infection (Lajoie et al., 2012). An important 
determinant of infection may be the number and the activation status of potential HIV 
target cells at the genital tract. Immune activation is a pivotal response against pathogen 
infections, however it may contribute to HIV susceptibility by increasing the number of 
HIV target cells to a critical mass for the establishment of an HIV infection. HIV entry 
into the host CD4+ T cells is dependent on the expression of the C-C chemokine 
receptors type 5 (CCR5) co-receptors (Cocchi et al., 1995). In a study carried out by 
Lajoie et al. (2014), HIV- uninfected female sex workers (FSW) expressed higher 
proportions of CD4+ T cells but had lower expression CCR5+ compared to non-FSW 
who had higher proportion of pro-inflammatory cytokines and CD4+ T cells expressing 
CCR5+ at the genital mucosa. Chemokines are low molecular weight glycoproteins (8-
12 kDa) which are known to regulate cell trafficking. These cytokines participate in 
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many physiological processes including the regulation of immune and inflammatory 
responses. Cytokines recruit leukocyte subpopulations selectively into a site of 
inflammation. Chemokines including Macrophage Inflammatory Protein-1 alpha (MIP-
1α), Macrophage Inflammatory Protein-1 beta (MIP-1β) which are produced by 
macrophages induced by bacterial endotoxins, and play a critical role during infection 
and inflammation, RANTES (regulated on activation, normal T cell expressed and 
secreted) and interferon-inducible protein (IP) 10 and have been reported to possess 
chemotactic activity for T cells with especially those bearing CCR5 receptors (Telda et 
al., 1996). 
 
 A heightened pro-inflammatory state at the genital tract has been hypothesized to 
enhance HIV susceptibility and transmission (Kahle et al., 2015). In a study carried out 
by Li et al., (2009) inflammatory cytokines (MIP-1α, MIP-1β and IL-8) in the genital 
tract of rhesus macaques were associated with establishment of simian immunodefiency 
virus (SIV) infection. Several reports identify a relationship between elevated 
concentrations of cytokines or chemokines and increased risk of HIV acquisition at the 
genital mucosa (Arnold et al., 2016, Masson et al., 2015b). Lajoie et al., (2012) 
demonstrated that HIV-exposed seronegative individuals had lower concentration of IL-
1α, MIG and IP-10 compared to HIV negative or positive groups. MIG and IP-10 also 
play a role in leukocyte trafficking of natural killer cells and both active and memory T 
cells. While cytokines play an essential role in cell signaling when mediating an 
immune response, these studies suggest that HIV is able to take advantage of the 
immune response to induce a progressive infection. The immune system of the female 
genital tract is an integrated part of the mucosal system, but is considerably distinct 
from characteristics observed systemically. Naranbhai et al., (2012) showed that 
systemic biomarkers of inflammation are associated with HIV acquisition among 
participants in the CAPRISA 004 trial. MIG, MIP-1α and MIP-1β were found to be 
significantly higher in the genital mucosa compared to the systemic compartment in 
FSW who have low basal immune activation (Naranbhai et al., 2012). These findings 
suggest that observations at the genital mucosa do not parallel those at systemic 
compartment, therefore since HIV, is mostly transmitted through heterosexual 
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intercourse, to gain greater and elucidative insights about HIV pathogenicity studies 
should be carried out using genital samples.  
Sexually transmitted infections (STIs) contribute to a great worldwide burden of 
morbidity and mortality (Tang and Rosenthal, 2010). The high prevalence of STIs has 
contributed to the disproportionately high HIV incidence and prevalence in Africa 
(WHO, 2009). Studies have shown that STIs and other genital infections have been 
associated with increased HIV susceptibility and transmission (Cohen, 2004, Mlisana et 
al., 2012a). STIs can compromise the integrity of the genital mucosa by causing micro-
ulcerations or inflammation, both increasing the amount of exposed HIV target cells at 
the genital mucosa (Cohen, 2004). The mechanisms that underpin the increase of 
preferential target cells at the genital tract are of important consideration in HIV 
acquisition. In this study the prime focus will be on the influence of immune activation, 
inflammatory responses and co-infections that compromise immunity to HIV infection 
at the genital tract.  
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1.2 Study Aim and Objective 
 
1.2.1 Specific aims 
a) To determine the relationship between the genital cytokines and the frequency of 
local activated immune cells.  
b) To determine the contribution of STI to levels of cellular and cytokine markers 
of inflammation. 
 
1.2.2 Study objectives: 
 To determine whether elevated frequencies of genital CD4+CCR5+ targets for 
HIV infection are associated with (1) increased concentrations of genital 
cytokine mediators of inflammation; (2) with T cell immune activation; and (3) 
with the presence of sexually transmitted infection in the same women. 
 
1.2.3 Hypothesis 
 Elevated levels of pro-inflammatory cytokines at the genital tract play a central 
role in the recruitment and or activation of immune cells into the genital tract. 
We also hypothesize that sexually transmitted infections in the genital tract 
prime the responses that trigger genital inflammation.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 HIV epidemic  
Almost seventy percent of the 36.7 million people globally infected with HIV-1 reside 
in sub-Saharan Africa (Figure 1.1), with women accounting for about 60% of these 
infections (UNAIDS, 2016). Heterosexual contact is the most common route of HIV 
transmission. Although exposure to HIV through sexual contact is not an efficient route 
of transmission, there are other aggravating factors that put women at increased risk for 
sexual transmission of HIV compared to their male counterparts (Gaskins, 1997, 
Mabala, 2006). In particular, young women (15–24 years) are much more likely to 
acquire HIV-1 than older women (Stirling et al., 2008). Young women acquire HIV-1 
infection 5-7 years before men and they are eight times more likely to be infected than 
their male counterparts (Abdool Karim et al., 1992, UNAIDS, 2012, UNAIDS, 2016). 
  
 
Figure 1.1: The prevalence of HIV in adults and young children (UNAIDS, 2015). 
People in Eastern and Southern Africa have the highest burden of the HIV epidemic, 
with more than one million new cases reported in 2015. 
 
It is thought that young women become infected with HIV-1 after fewer acts of 
unprotected sex (Glynn et al., 2001, Pettifor et al., 2005), and several biological risk 
factors that may predispose women to become infected with HIV-1 have been proposed 
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(Chersich and Rees, 2008). The surface area of the lower reproductive tract exposed 
during sexual intercourse in women is greater than the reproductive tissue of men, 
which may increase surface area exposed, time in contact with infectious fluids post-
coitus, and exposure of intraepithelial HIV-1 target cells to pathogens (Yi et al., 2013). 
Microabrasions in the genital tract, in the comparatively more fragile and less 
keratinized epithelial barrier, may be more common in women than men and provide a 
portal for pathogen entry (Stanley, 2009). Cervical ectopy (particularly to younger 
women) may facilitate increased exposure of HIV-1 target cells to pathogens in the 
lower reproductive tract during sex (Critchlow et al., 1995). Finally, the presence of co-
factors such as sexually transmitted infections (STIs), often asymptomatic and therefore 
untreated in women, also increase the risk of HIV-1 infection (Cohen, 2004, McKinnon 
et al., 2011).  
 
2.2 The female genital tract 
 
The female genital tract is a unique environment that has the ability to respond sharply 
to infections that are generally transmitted in seminal plasma or during sexual contact, 
whilst at the same time being tolerant to allogenic spermatozoa (Haase, 2010, Haase, 
2011). The female genital tract (FGT) represents components of the common mucosal 
system, but with features which are distinct from other mucosal tissues, these include; 
adaptions of dealing with the presence of residential microbiota as well as responding to 
challenges imposed by bacteria, yeast and viruses (Gupta & Kumar, 2012). The FGT is 
composed of specialized components which include: upper reproductive tract part which 
is composed of a single layer of columnar epithelium, transitional endocervix and the 
lower reproductive tract (vagina and ectocervix) composed of multilayered stratified 


















Figure 1.2: The anatomical structure of the female genital tract. Components of the 
FGT include; the lower reproductive tract which consist of the vagina and the 
ectocervix. The upper reproductive tract which is composed of both the uterus and 
cervix. (Iwasaki, 2010). 
 
The susceptibility of these components within the female genital tract to infections 
differs. Between the ectocervix and endocervix, is the transformation zone. Within this 
zone the squamous epithelium changes to a single layer of the columnar epithelium. 
This region is described as being more vulnerable to infection due to a high number of 
activated lymphocytes and lymphoid aggregates present in the presence of various 
pathogens (Weisesenbacher et al., 2013). Immune T cells are unevenly distributed in the 
female genital tract (Johansson et al., 1999). Compared to peripheral blood, the female 
genital tract contains more CD8+  T cells than CD4+ T cells. Other immune cells present 
include macrophages, dendritic cells,  neutrophils and natural killer cells which are part 
of the innate immune system in the genital mucosa (Amjadi et al., 2014). This means 
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that the female genital tract is an active site equipped to defend itself against invading 
pathogens 
 
2.3 HIV-1 transmission across the female genital tract 
 
The mucosal epithelium of the lower female reproductive tract provides the first line of 
defense against pathogen entry and mediates the initial host immune response against 
STIs, including HIV-1 (Kaushic, 2011, Wira et al., 2005a, Wira et al., 2005b). This is 
also the surface through which HIV-1 is transmitted from an HIV-1 infected woman to 
her sexual partner (Yi et al., 2013). The genital mucosa is also thought to serve as a 
discrete site for HIV-1 infection, replication and pathogenesis by providing the virus 
with a steady supply of susceptible target cells (Zhang et al., 1999). The epithelial 
barrier of the genital mucosa is also thought to be influenced by hormones, 
inflammation and infection (Murphy et al., 2014). Acute HIV-1 infection has been 
associated with increased genital tract inflammatory cytokine responses in women 
(Roberts et al., 2012), that may result in increased permeability of the mucosal epithelial 
barrier, allowing HIV-1 easier passage across the mucosal epithelium (Nazli et al., 
2010). Cell-free virus has also been shown to move between the upper layers of the 
“leaky” squamous epithelial barrier (Hladik and Hope, 2009). It has been suggested that 
transcytosis of HIV-1 may occur through polarized columnar epithelial cells and 
squamous epithelial cells (Hladik and Hope, 2009). However, other studies have found 




2.3.1 Mucosal immune system and HIV 
The immune system is a host defense mechanism to eradicate infections and pathogens. 
The mucosal system is an integrated part of the body’s immune system, is however 
distinct in that, it acts both as a natural barrier and interacts with the external 
environment.   
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Different factors influence the host susceptibility to HIV infection. HIV infection is 
dependent on the hosts’ chemokine co-receptor CCR5+ on CD4+ T cells to initiate a 
productive infection. It has been shown that individuals with mutations on the CCR5+ 
gene are highly resistant to HIV infection (Samson et al., 1996). Furthermore, high-risk 
seronegative individuals with suppressed T cell immune activation demonstrated low 
HIV susceptibility (Koning et al., 2005).  
 
Immune activation, characterized by T cell activation and elevation of pro-inflammatory 
cytokines has been suggested as a hallmark of HIV infection (Lawn et al., 2001). In a 
study conducted by Naranbhai et al., (2012), though the Tenofovir gel showed 39% 
efficacy, it was shown that women with high immune activation and inflammation were 
associated with HIV acquisition. Immune activation, is pivotal in eradicating pathogens 
and infectious agents. However, in the case of HIV infection, it may contribute to HIV 
susceptibility by increasing the number of HIV target cells to a critical mass for the 
establishment of an HIV infection (Lajoie et al., 2014). Cytokines play a crucial role 
modulating pro-inflammatory and anti-inflammatory immune responses.  Elevated 
concentration of pro-inflammatorty cytokines including chemokines have been show to 
be associated with  HIV acquisition at the genital mucosa (Arnold et al., 2016, Li et al., 
2009a, Masson et al., 2015a). The common route of HIV transmission is through 
heterosexual contact. The presence of HIV target cells and the role of cytokines in the 
genital mucosa suggest their significance in HIV transmission. 
 
2.4 Genital inflammation and HIV risk 
 
Understanding mucosal risk factors in the female genital tract are critical for 
understanding STI/HIV susceptibility. In the CAPRISA 004 1% tenofovir microbicide 
trial, women who became HIV-infected during the trial had significantly elevated 
genital tract inflammatory markers prior to HIV-infection (evidenced by increased 
concentrations of MIP-1α, MIP-1β, IL-8, and IP-10, determined by logistic regression 
and principle component analysis), independent of study arm and age (Masson et al.; 
2015b). Furthermore, detection of either MIP-1α or MIP-1β in cervicovaginal lavage 
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(CVL) was associated with >3 fold increased odds of HIV infection (Masson et al., 
2015b). A recent study demonstrated high levels of inflammatory cytokines (including 
IL-1α, IL-6, IL-1β and IP-10) in endocervical secretions of women with chlamydial 
infection compared to treated women (Sperling et al., 2013). In the CAPRISA 002 
Acute Infection cohort we demonstrated that several inflammatory cytokines (including 
MIP-1β, RANTES and TNF-α) were significantly associated with both symptomatic 
and asymptomatic STIs, and that these inflammatory cytokines were independent 
predictors of HIV acquisition in prospective follow-up, after accounting for multiple 
comparisons (Masson et al., 2014, Mlisana et al., 2012b). However, STIs accounted for 
only 20% of genital inflammation associated with HIV acquisition risk in the CAPRISA 
trial (Masson et al., 2015b). Therefore, investigating and understanding other causes and 




2.5 Genital inflammation, immune activation, HIV shedding and disease 
progression 
 
 HIV infection has been associated with increased mucosal and systemic inflammatory 
cytokine responses in women (Roberts et al., 2012). Inflammatory responses have also 
been shown to enhance HIV pathogenesis, by recruiting highly activated HIV target 
cells to the site of initial viral infection and replication (Li et al., 2009b, Meier et al., 
2007, Abel et al., 2005). In macaques infected with SIV, cervicovaginal concentrations 
of MIP-1α, MIP-1β and MIP-3α resulted in recruitment of CCR5+ and CD4+ T cells in 
the endocervical epithelium (Li et al., 2009b). Furthermore, spread of SIV-infected cells 
from the genital mucosa to ensure a productive systemic infection, correlated with this 
pro-inflammatory cytokine gradient (Li et al., 2009b). In humans, concentrations of IL-
1β, IL-6, and IL-8 in CVLs from HIV acutely infected women correlated inversely with 
CD4+ T cell counts in blood, suggesting the level of both mucosal and systemic 
inflammation present during acute infection predicted adverse CD4 decline during acute 
infection (Bebell et al., 2008). Furthermore, increased recruitment of activated HIV 
target cells to the genital epithelium was shown to facilitate local HIV replication and 
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result in increased local genital HIV shedding from HIV infected women, potentially 
placing their male partners at higher risk of HIV infection (Gordon et al., 1999, Rottman 
et al., 1997). In both humans and non-human primates studies, higher levels of T cell 
activation in blood and plasma viral loads during acute infection predicted faster rates of 
mucosal and systemic CD4 cell decline and more accelerated disease progression 
(Douek et al., 2009, Hazenberg et al., 2003, Brenchley et al., 2004, Silvestri et al., 
2003). A better understanding of how higher local and systemic viral loads increase risk 
for partner infection could lead to better interventions aimed at blocking HIV-1 
transmission from an infected women to her partner. In addition, it would also identify 
therapeutic targets to block male-to-female transmission. 
 
2.6 Consequences of Sexually transmitted infections in the female genital tract  
Multiple factors are known to influence the genital mucosal barrier. Sexually 
transmitted infections (STIs) at the genital mucosa are among these factors, and 
represent one of the most widespread infectious diseases and pose a major health burden 
in morbidity and mortality (Tang and Rosenthal, 2010). According to the WHO (2016), 
it is estimated that over a million STIs are acquired per day globally (Figure 1.3). In 
addition, there is an estimated 357 million new STIs; C. trachomatis (131 million), N. 
gonorrhea (78 million), T. pallidum (6 million) and T. vaginalis (142 million) among 
young people between the age of 15-49 globally per year. Although measures have been 
put into place to fight STIs, they still continue to contribute disproportionately to high 
HIV incidence and prevalence in Africa (WHO, 2009). Studies have shown that STIs 
and other co-infections in the genital tract are associated with increased HIV 
susceptibility and transmission (Cohen et al., 2010, Mlisana et al., 2012b, Ramjee et al., 
2015). STIs can compromise the integrity of the genital mucosa by causing micro-
ulcerations or inflammation, both increasing the amount of exposed HIV target cells at 














Figure 1.3: Global estimates of new cases of curable STIs; syphilis, trichomoniasis, 
chlamydia and gonorrhea (WHO. 2016). Africa is among the regions with the highest 
number of STIs cases. 
 
Not all STI are symptomatic. In developing countries such as South Africa, 50% of 
infections are asymptomatic (Wilkinson et al., 1999) and untreated STIs can result in 
such dire consequences to women as pelvic inflammatory diseases and tubular factor 
infertility. In developing countries, they rely on syndromic management of  STIs. In 
such resource-poor settings etiological diagnosis is expensive and requires specialized 
expertise (WHO, 2011). A randomized trial in Tanzania demonstrated that STI 
treatment reduced HIV incidence by 40% within the population (Kamali et al., 2003; 
Gregson et al, 2007; Celum et al 2008). Better understanding of the genital mucosal 
immune system is of paramount importance since STIs have been shown to increase 
HIV risk acquisition and disease progression, and likely facilitate a crucial role in the 
recruitment and activation of HIV target cells in the genital tract.   
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CHAPER 3. RESEARCH DESIGN AND METHODOLOGY 
 
3.1. Study Participants  
This study investigated biomarkers of inflammation in a subset (n=166) of participants 
of the CAPRISA 008 open-label randomized controlled trial that assessed the 
implementation effectiveness and safety of 1% Tenofovir (TFV) gel. The random 
convenience sample of CAPRISA 008 trial participants were all above the age of 18, 
were HIV negative at screening, and within 3 months prior to screening had at least one 
coital act. All the participants previously participated in the CAPRISA 004 study, and 
none of the women were pregnant. The study was conducted at the urban CAPRISA 
eThekwini and rural CAPRISA Vulindlela Clinics, and other public sector family 
planning services in KwaZulu-Natal, South Africa. The study was conducted in 
accordance with conditions stipulated by the ethics and regulatory committees upon 
approval. 
 
3.1.1 HIV testing at screening and enrolment  
During screening and enrolment, participants underwent voluntary counselling prior to 
HIV testing. For HIV-1 screening blood samples were collected for rapid HIV antibody 
tests. Two antibody HIV tests were conducted at screening and enrolment, a 
confirmatory HIV enzyme immunoassay (EIA) (BEP 2000; Dade Behring, Marburg, 
Germany) was performed for participants who had discordant result and based on the 
result obtained participants were classified into the HIV-negative cohort or HIV follow-
up care services. 
 
3.2 Biological Specimen collection and Processing 
All specimens in this study were collected at enrolment, approximately 1 month after 
screening for inclusion into the CAPRISA 008 trial. None of the participants were using 
1% TFV gel at the time of sampling. Cervical cytobrushes and cervicovaginal lavage 
(CVL) specimens were collected for the assessment of immune activation profiles in the 
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genital tract. Vulvovaginal swabs were collected for testing the presence of sexually 
transmitted infections. Specimens were not collected at the time of menstruation or if 
women were pregnant. All specimens were kept on ice and transported to the CAPRISA 
laboratory within approximately 4 hours. 
 
3.2.1 Cervicovaginal Lavage  
CVL specimens were collected and processed as previously reported (Bebell et al., 
2008). A volume of 10ml of sterile saline was used to bathe the cervix. The resulting 
fluid at the posterior fornix was aspirated using a sterile plastic bulb pipette and was 
transferred to sterile conical tubes.  CVLs were transported to the CAPRISA laboratory, 
where they were centrifuged at 800 x g for 10 minutes  and the supernatant was stored 
in 1ml aliquots at -80°C. 
 
3.2.2 Vulvovaginal Swab 
Vulvovaginal swabs were collected at the vulva using sterile cotton wool swabs 
(Dacron) and were placed into 1.5ml cryovial tubes that contained 0.4ml of PBS. 
Specimens were stored at -80°C. 
 
3.2.3  Cytobrushes 
Cervical mucosal mononuclear cells (CMC) were collected using a Digene Cervical 
sampler. A single 3600 rotation of the cytobrush was required to collect cells from the 
cervical os. The cytobrushes were placed in a 15ml tube (Griener) and immersed into 
RPMI (Roswell Park Memorial Park Institute Medium 1640, SIGMA-ALDRICH) 
supplemented with 10% heat inactivated Fetal Bovine Serum (FBS) and 5mM 
glutamine, penicillin and streptomycin, hence forth referred to as R10 media. 
Specimens contaminated with visible blood were discarded. The cytobrushes were 
processed in Biosafety Laminar Flow Hoods (ESCO class II, BS, LABOTEC) using 
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aseptic techniques. First, the presence of contaminating sperm was investigated by 
placing a drop of the sample’s medium on a glass slide, covering with a slip and 
viewing under a light microscope at 100x magnification (Olympus, model 
CVL31RBSF). Cells from the cytobrush were dislodged by pipetting vigorously (up and 
down at least 10 times) using a Pasteur Pipette. The cytobrush was washed similarly for 
a further 5 times with 2ml R10 media and the dislodged cells were collected by 
centrifugation at 1400rpm (400xG) for 10 minutes at 40C.The supernatant was 
discarded and the pellet resuspended in 500µl of R10 media for counting of cells before 
staining for flow cytometry. 
 
3.2.4 Cell counting using Trypan Blue Exclusion Method  
From the 500µl cell suspension, a manual counting technique was used to count the 
number of viable mononuclear cells. Trypan blue staining technique was used to 
selectively distinguish between viable and dead cells. A volume of 15µl of the cell 
suspension was mixed with 15µl of Trypan Blue (WhiteSci, PTY. Ltd.) and cells were 
rested in the dye for 2 minutes to allow for optimal staining. The solution was 
transferred into the counting chambers of Fastread slides (Davis Diagnostic PTY LTD.) 
and viewed under a light microscope at 400x magnification. Viable cells have an intact 
cell membrane and because the dye does not transverse through the membrane (Strobe, 
2001), viable cells will appear colourless. In contrast dead cells do not have an intact 
cell membrane therefore the stain transverses the membrane and they will be stained 
blue. In each counting chamber two squares were selected from the grid and were used 
to count the average number of lymphocytes. 
 
3.3 Investigation of cellular activation by flow cytometry 
 
3.3.1 Surface staining of cellular immune markers 
Cells isolated from cytobrushes and whole blood were transferred to wells of a V-
bottom 96 well plate for staining. The cell pellets were resuspended using 150µl PBS 
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and the plate was centrifuged at 2100rpm (833xG) for 3min at 40C. The supernatant was 
discarded by quickly and firmly flicking liquid contents onto absorbent paper in a 
bucket. Steps involving antibody-conjugated fluorochromes were conducted in the dark 
as these compounds are light sensitive. Live/dead stain Fixable Violet Dead cell stain 
kit (Molecular probes, Life technologies, USA) was used to differentiate between live 
and dead cells in a respective well. A working stock was prepared by diluting the vivid 
in de-ionised water to make up a 1:40 dilution. This was further diluted 1:20 in PBS and 
a final volume of 50µl vivid was added to the cell solutions in their respective wells of 
the 96-well plate. The cells suspensions were incubated at 40C for 20 minutes to allow 
for optimal antibody binding. Pellets were washed with 200ul/well cold wash buffer 1% 
FBS in phosphate-buffered saline (PBS) and the pellets were resuspended by mixing.  
The plate was centrifuged at 2100rpm (833xG) for 3min at 40C and the supernatant was 
discarded by flicking.  
 
The mononuclear cells were then stained extracellularly with a cocktail of the antibody-
conjugated fluorochromes: Pacific Blue–labelled anti-CD14 (BD Bioscience) and 
Pacific Blue labelled anti-CD19 (BD Bioscience), fluorescein isothiocyanate (FITC)-
labelled anti-CD8 (BioLegend), allophycocyanin tandem dye (APC-H7)-labelled anti-
CD3 (BD Bioscience), peridinin-chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)-
labelled anti-CD4 (BD Bioscience),  eF605-labelled anti-CD16 (eBioscience) and 
phycoerythrin cyanine 7 labelled anti-CD56 (BD Bioscience). The antibodies were pre-
tritrated and added at a volume of 2µl/well for all besides anti-CD4, in which only a 
volume of 1µl constituted to the total volume (13µl) of the antibody cocktail added per 
well. The plate was incubated for 20mins at 4oC in the dark to allow for antibody 
binding. 
 
3.3.2 Intracellular staining of cellular immune markers 
After incubation, excess surface antibody was removed by washing the cells with a 
volume 200µl wash buffer and centrifuged at 2100rpm (833xG) for 3min at 40C The 
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supernatant was discarded and the pellets were resuspended in 100µl 
Cytofix/CytopermTM (BD Bioscience) prior to incubation at 4oC for 20min in the dark. 
A volume of 150µl Perm-Wash Buffer (BD) was used to resuspend cells, prior to 
centrifugation at 2100rpm (833xG) for 3min at 40C. The supernatant was flicked out 
and subsequently a cocktail of intracellular staining antibodies was added to each 
respective well.  A volume of 2µl of each of the following antibodies was added per 
well: T cell activation markers eF655-labelled anti-CD38 (eBioscence) and 
phycoerythrin (PE)-labelled anti-HLA-DR (eBioscience), and proliferation marker 
Brilliant violet 700 (BV700) labelled anti-Ki67 (BioLegend). Finally, a volume of 10µl 
of allophycocyanin (APC) labelled anti-CCR5 which is a chemokine receptor was 
added to make up a total volume of 16µl/well of the intracellular antibody cocktail. 
 
After 20 minutes of incubation at 4oC, a volume of 200µl Perm-Wash Buffer was used 
to resuspend the cells. The plate was then centrifuged at 2100rpm (833xG) for 3min at 
40C and the resulting supernatant discarded by flicking. Cells were finally resuspended 
in 100µl CellFix (BD) before being transferred into a clean, labelled FACS tubes (BD). 
The wells were washed with a further 50µl of BD CellFix and added to the 
corresponding FACs tube prior to data acquisition using an LSRII flow cytometer (BD 
immunocytometry Systems). 
 
3.3.4 Preparation of compensation beads 
Compensation beads (BD Bioscience) were prepared for each antibody-conjugated 
fluorochrome used. Briefly, the compensation beads were vortexed and 1 drop of the 
negative and positive beads were added to each of the FACs tube. The same volume of 
antibody used for extracellular and intracellular staining was added to the appropriately 
labelled FACS tube for that antibody. 
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3.3.5 Data acquisition 
The samples were acquired on a LSRII flow cytometer (BD immunocytometry 
Systems), and data was analysed using FlowJo Software (Tree Star). Appendix, Figure 
2 depicts a representative schematic of the gating strategy. Fluorescence minus one 
(FMO) controls were prepared using unrelated PBMCs from liquid nitrogen. FMOs 
contain all the markers in the panel except the one of interest and in flow cytometery are 
ideal for showing gating boundaries. Briefly PBMCs were thawed and stained with 
flourochrome-conjugated antibodies as follows: one FACs tube contained all the 
antibodies in the panel and the other three subsequent FACs tubes had all the antibodies 
(did not have either anti-CD38, anti-CCR5 or anti-HLA-DR) in the panel except for one 
antibody. Specimens with a CMCs CD3 T-cell event count below a threshold level of 
100 were excluded. 
 
3.4 Measurement of genital tract cytokine concentrations 
Cytokine measurements were conducted on these specimens using the Bio-Rad 27 and 
21-Plex Pro Cytokine, Chemokine, and Growth (Bio-Rad, U.S) kits as per 
manufacturer’s instruction. In total a panel of 48 cytokines was used to assess 
cytokine/chemokine profiles these included pro-inflammatory cytokines (IL-1α, IL-1β, 
IL-6, IL-12p40, IL-18, MIF, TNF-α, TNF-β and TRAIL), chemokines (CTACK, 
Eotaxin, GRO-α, IL-8, IL-16, IP-10, MCP-1, MCP-3, MIG, MIP-1α, MIP-1β, 
RANTES, INF-α2), growth factors (B-NGF, FGF-basic, G-CSF, GM-CSF, HGF, IL-3, 
IL-7, IL-9, LIF, M-CSF, PDGF-BB, SCF, SCGF-β, SDF-1α, VEGF, adaptive cytokines 
(IFN-γ, IL-2, IL-4, IL-5, IL-13, IL-15, IL-17, IL-2Rα ) and anti-inflammatory cytokines 
(IL-10 and IL-1Rα). 
 
3.4.1. Multiplex ELISA plate preparation 
Thawed CVLs and plasma specimens were filtered by centrifuging at 10,000rpm for 10 
minutes in Spin-X® 22µm centrifuge tubes (Costar®, USA). A total volume of 300µl 
per filtered sample was placed in wells of a v-bottomed 96-well (Costar®, USA) 
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“master plate” and kept at 40C until use. Samples were plated on the master plate to 
limit variability in time of sample exposure to magnetic beads. A total of 6 master plates 
were prepared, 6 plates for the 21 and 27-Plex Pro, Chemokine and Growth kits. Each 
Luminex plate included 4 duplicates genital samples to investigate reproducibility of 
measurements within a plate. Four genital samples were each replicated on a subsequent 
plate to investigate reproducibility of cytokine measurements across plates. A 
representative luminex plate is depicted in table 1 below. 
 
Table 1. Representative diagram for plate design showing how standards, blanks, 







3.4.2  The Multiplex ELISA Assay 
Figure 2.1 depicts a flow diagram summarizing the assay procedure. Briefly assay 
buffer, wash buffer and standard were brought to room temperature (RT), while other 
kit reagents including detection antibody, detection antibody diluent, streptavidin-
phycoerythrin and the magnetic beads were kept at 4oC until use. Briefly, a volume of 
50µl/well 10x magnetic beads were added to a 96 well flat-bottomed plate and washed 
twice with 100μl of Bio-PlexTM Wash Buffer using Bio-Plex ProTM II (BIO-RAD) 
automated washing station. Once prepared, the standards and blanks were each vortexed 
(VORTEX GENIE 2, Scientific Industries) for a further 10 seconds before adding 50μl 
to an appropriate respective well on the flat-bottomed plate. Samples from the master 
plate were resuspended using a pipette before transferring 50µl/sample to the designated 
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well. Once sealed and covered with foil to protect from light, the plate was incubated at 
RT in the dark on an Orbital shaker SSL1 (Stuart®) at 850rpm for 30minutes. 
Thereafter samples were washed 3 times with 100ul Bio-PlexTM Wash Buffer using 
Bio-Plex ProTM II (BIO-RAD) automated washing station. A volume of 25µl detection 
antibody was added per well and the plates were sealed and covered with foil prior to 
being incubated at RT on a mechanical shaker at 850rpm for 30minutes. 
 





Plates were washed 3 times as before, and a volume of 50ul PE-conjugated streptavidin 
was then added/well. The plates were incubated at RT on a mechanical shaker at 
850rpm for 10minutes. Thereafter plates were washed 3 times as before, and a volume 
of 125ul/well Assay buffer was added in preparation for data acquisition using the Bio-
Plex® MAGPIXTM MultiPlex Reader (XMAP TECHNOLOGY, BIO-RAD). 
 
3.4.2 Standard preparation 
 
Briefly, a volume of 500µl of the standard diluent was added into the lyophilized 
standard and vortexted intensively for 3 seconds before being incubated on ice for 30 
minutes. A set of 10 polypropylene tubes (BD FalconTM) were used for the standards. A 
volume of 72µl was added to the first tube and subsequently a volume of 150µl of the 
standard diluent was added to the remaining tubes. After incubation the reconstituted 
standard was vortexed and 1:4 serial dilutions was performed by transferring 128µl to 
the first tube and subsequently transferring a volume of 50µl between each tube. 
 




3.4.3 Bead preparation 
Coupled beads were prepared by adding a volume of 575µl of 10X beads to a volume of 
5175µl of assay buffer to make up a total volume of 5750µl.   The working bead 
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solution stock was vortexed at medium speed for 20 seconds and 50μl was added to 
each well. 
 
3.4.4 Detection antibody preparation 
A detection antibody solution was diluted by adding a volume of 300µl of 10X 
detection antibody to 2700µl of the detection antibody diluent. The working antibody 
stock was vortexed for a period of 15-20 seconds before transferring 25µl to each well. 
 
3.4.5 Streptavidin-PE preparation 
A working stock of Streptavidin-PE was prepared by adding a volume of 60µl 100x 
beads to a volume of 5940µl of the assay buffer.  A volume of 50µl/well vortexed 
Streptavidin-PE working stock was added to each well.  
 
3.5  STI testing 
Swabs were collected and screened at National Institute for Communicable Diseases 
(NCID; Johannesburg, South Africa) to determine the STI prevalence of N. 
gonorrhoeae, C. trachomatis, T. vaginalis and M. genitalium within the cohort using 
multiple polymerase chain reaction (multiplex PCR). 
 
3.6  Statistical Analysis 
Statistical tests were performed on GraphPad prism version 5. Mann–Whitney U tests 
and Chi square tests were performed for independent sample comparisons. Adjustment 
for multiple comparisons was performed using a step-down approach. All tests were 2-
tailed, P value < 0.05 were considered significant 
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CHAPTER 4. RESULTS 
 
4.1 Clinical and socio-behavioral characteristics of the study participants 
The baseline socio-demographic and clinical characteristics of the participants are 
summarized in Table 2A. and 2B. below. A total of 166 participants were included in 
this study.  The mean age of women in this study was 29 years, and had experienced 
their first sexual encounter at the mean age of 18 years.  Less than 5% of women 
attained a tertiary qualification. All but one participant had genital swabs available for 
STI diagnosis (n=165). The overall prevalence of laboratory diagnosed STIs (N. 
gonorrhoeae, T. vaginalis, C. trachomatis and/or M. genitalium) was 18.7%. within 
women in this cohort (n=165). C. trachomatis had the highest prevalence at 6.7% 
(n=11), followed by M. genitalium at 4.8% (n=8) and N. gonorrhoeae and T. vaginalis 
both at 3% (n=5). In addition, condom usage was substantially below 50%. The overall 
immune T cell activation status was measured on CD3+, CD4+ and CD8+ population 
using flow cytometry in 120 eligible women. Activation markers Ki67+, CCR5+ and 
dual expression of CD38+/HLA-DR+ were measured on these T cell subsets. The 
frequencies of CCR5+ and CD38+/HLA-DR+ activation markers were higher on CD4+ T 
cell sub populations, with median (IQR) frequencies of 35.3% (0.30-51.53%) and 










Table 2A. Baseline clinical and socio-behavioral characteristics in the CAPRISA 
008 study. 
Characteristic Value 
Number of participants (N) 166 
Age (mean±SD) 29.65±5.61 
Education complete [n (%)]:  
Less than primary school  40.5%,(66) 
Primary school complete  2.5% (4) 
High school complete  52.2% (85) 
Tertiary complete  4.9% (8) 
Sexual behavior:  
Age (year) at first sexual encounter [median (IQR)] 18 (16-19) 
Condom usage [% (n)]:  
Always 37.4% (61) 
Sometimes 49.7% (81) 
Never 12.9% (21) 
STIs tested [%, (n =165)]:  
Prevalence of chlamydia trachomatis  6.7% (11/165) 
Prevalence of Neisseria gonorrhoeae  3% (5/165) 
Prevalence of Mycoplasma genitalium  4.8% (8/165) 
Prevalence of Trachomonas vaginalis 4.8% (8/165) 
  
Overall sexually transmitted infections (%) 18.07% 
 





Table 2B. Baseline activation in the CD3+, CD4+ and CD8+ population from live 
lymphocytes in the genital mucosa of CAPRISA 008 participants (n=120).  
 
Cellular phenotype Median % (IQR) 
Frequency of live CD3+ from 
lymphocytes 
11.65 (5.53-21.53) 
CD3+ T cell population  
CD3+Ki67+ 30.2 (0.371-48.05) 
CD3+CCR5+ 33.05 (20,08-59.25) 
CD3+CD38+/HLA-DR+ 2.17 (0.40-6.78) 
CD4+ T cell population  
CD3+CD4+  45 (33.45-55.38) 
CD4+Ki67+ 32.25 (0.30-51.53) 
CD4+CCR5+ 38.3 (16.78-60.40) 
CD4+CD38/HLA-DR+ 2.40 (0.50-15.95) 
CD8+ T cell population  
CD3+CD8+  26.3 (16.18-36.33) 
CD8+Ki67+ 44.5 (0.00-71.35) 
CD8+CCR5+ 33.75 (17.8-55.18) 
CD8+CD38/HLA-DR+ 1.44 (0.00-11.45) 
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4.2 Cellular activation and inflammation in CAPRISA 008 participants. 
Healthy women from sub-Saharan Africa are known to have increased levels of immune 
activation compared to women in the United States (Cohen et al., 2010). Immune 
activation has been found to be a significant factor in HIV acquisition (Naranbhai et al., 
2012) and disease progression (Hazenberg et al., 2003). The presence of activated CD4+ 
T cell targets for HIV infection at the genital tract may partially explain the increased 
risk of HIV acquisition in these women. In this study and others, high levels of T cell 
activation are defined by the dual expression of CD38+ and HLA-DR+ activation 
markers (Jarrett et al., 2015, Jaspan et al., 2011). To compare women with low and high 
levels of T cell activation at the genital tract, women with high levels of immune 
activation were defined as those with CD38+/HLA-DR+ frequencies above the 75th 
percentile (n=30), while those below the 25th percentile (n=30) were defined as having a 












Figure 3.1: The distribution frequency of activated T cells defined by dual 
expression of CD38+ and HLA-DR+ on each patient and the comparison of genital 
immune T cells between women with high and low activation status. A, B & C is a 
scatter plot showing women who had high (blue box) and low (green box) T cell 
activation status on CD3+ and CD4+ (n=30 both 75th and 25th percentiles) and CD8+ 
[n=30 (75th percentile), n=35 (25th percentile] in the cervix (Figure 3.1A, B & C 
respectively). A scattered dot plot showing the frequency of  activated (CD38+/HLA-
DR+); CD3+, CD4+ and CD8+ T cell subpopulations expressing either CCR5+ or both 
Ki67+/CCR5+  between  women with high (red dots corresponding with the blue box; 
75th percentile CD38+HLA-DR+) and women who had low (green dots corresponding 
with the green box; 25th percentile CD38+HLA-DR+)  immune activation status (Figure 
3.1D, E & F). The dark solid lines represent the median, upper and lower quartile range 
T-cell activation status which were compared using the Mann-Whitney U test. The 
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Women with high T cell activation status had elevated frequencies of CD4+ T cells 
expressing CCR5+ (p<0.0001) compared to women with low T cell activation status 
(Figure 3.1B). Similarly, women with high activation status had significant proportions 
of proliferating (p<0.0001) CD4+CCR5+ T cells at the genital tract (Figure 3.1D). These 
data identify women with high levels of activation as potentially more at risk for HIV 
infection by virtue of their increased frequencies of activated and replicating targets for 
HIV infection. The same trend was observed in CD3+ and CD8+ T cell populations, 
where women who had high T cell activation status had significant proportions of CD3+ 
CCR5+ (p<0.0001) and CD8+CCR5+ (p<0.0001) T cells. Proliferating CD3+CCR5+ 
(p<0.0001) and CD8+ CCR5+ (p<0.0001) T cell were also significantly elevated in 
women who had T cell activation status (Figure 3.1E & F).  
 
To assess differences between women with high and low T cell immune activation 
status, cytokine/chemokine profile and the prevalence of STIs were measured in each 
group. There were no overwhelming significant observations in cytokine/chemokine 
concentration expression profile between women with high immune and low immune 
activation at the genital tract. However, women with highly activated overall CD3+ T 
cell status had significantly higher concentrations of pro-inflammatory cytokines MIF 
(p=0.0217) and IL-12p70 (p=0.0173), the chemokine MCP-1 (p=0.0024), and the 
regulatory cytokine IL-10 (p=0.0064) compared to women with a low T cell activation 
status (Appendix: Table 3.3.2 A). Only the growth factor M-CSF, and the adaptive 
cytokine IL-17 were reduced in women with high activation status relative to those with 
low levels of CD3+ T cell activation (Appendix: Table 3.3.2 A). In women with highly 
activated CD4+ T cell populations, significantly higher concentration of cytokines Basic 
FGF (p=0.0491), IL-10 (p=0.0362), MCP-3 (p=0.0180), IL-13 (p=0.0468), and MIF 
(p=0.0235) were observed relative to women with low levels of activation; and lower 
levels of chemokine M-CSF and b-NGF were observed (Figure 3.2; Appendix: Table 
3.3.2. B). The cytokines MIF (p=0.0056), IL-10 (p=0.0168), IL-12p70 (p=0.0145), 
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MCP-1 (p=0.0326) and IL-5 (p=0.0123) were elevated in women with high levels of 
CD8+ T cell activation, while concentrations of M-CSF (p=0.0229), b-NGF (p=0.0186) 
and IL-15 (p=0.0203) were reduced relative to women with low levels of CD8+ T cell 
activation (Appendix: Table 3.3.2 C). However, after adjustment for multiple 
comparisons none of the observations maintained statistical significance. Interestingly, 
none of the cytokines associated with CCR5+ recruitment (MIP-1a, MIP-1b, RANTES, 
IP-10) differed in concentration between women with high and low levels of cellular 
activation. Further, there was no correlation between CCR5+ frequencies and 
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Figure 3.2. Representative diagram showing the cytokine/chemokine expression 
between women with high and low T cell immune activation status in the CD4+ T 
cell population. A scatter plot of cytokine profile between women with high immune 
(green dots) and low immune (red dots) activation at the genital tract. The dark solid 
lines represent the median, upper and lower quartile range. The cytokine profile 
between women with high and low immune activation was compared using the Mann-
Whitney U test. An asterisk (*) represent significant P values ≤ 0.05 were significant 
prior to adjustment for multiple comparisons, however none of the observations upheld 









Another biological factor that might explain high incidence of HIV rates in young South 
African women include genital inflammation (Arnold et al., 2016, Masson et al., 2015). 
Cytokines recruit leukocyte subpopulations selectively into a site of inflammation 
(Turner et al., 2014). Chemokines, including MIP-1α, MIP-1β, RANTES and IP-10, 
have been reported to possess chemotactic activity for T cells (Telda et al., 1996). 
While cytokines play an essential role in cell signaling when mediating an immune 
response, these studies suggest that HIV is able to take advantage of the immune 
response to induce a progressive infection (Kahle et al., 2015, Li et al., 2009).  
 
Previous data from CAPRISA showed that the risk of HIV acquisition was significantly 
higher in women with inflammation at the genital tract (Masson et al., 2015), so genital 
inflammation was investigated in women with high and low levels of cellular activation 
in this study. Genital inflammation was defined by elevated levels of at least 5 of 9 pro-
inflammatory (IL-1α, IL-1β, IL-6 and TNF-α) and chemotactic (MIP-1α, MIP-1β, IP-
10, IL-8 and MCP-1) cytokines above the 75th percentile as described by (Masson et al., 
2015). By this definition, 17.5% (n=20) of women had genital inflammation compared 
to 82.5% (n=94) of women who had no genital inflammation.  
 
Furthermore, when the relationship in the frequency of activated CD4+ T cell population 
was compared between women with inflammation (n=20) and those without 
inflammation (n=94), data shows that there was no statistical significant difference 






Figure 3.3. Representative diagram of the relationship between activated CD4+ T 
cell population between women with inflammation and those who did not have 
inflammation. A scatter plot showing a comparison of activation markers CCR5+, 
CD38+, Ki67+, HLA-DR+ and dual expression of CD38+/HLA-DR+ on CD4+ T cell 
population between women with inflammation (green dots) and those without 
inflammation (red dots). The comparison was done using the Mann-Whitney U test. The 




4.3 Sexually transmitted infections as potential drivers of genital immune 
activation and inflammation. 
To investigate an association between inflammation and STIs, the prevalence of 
common discharge-associated STIs N. gonorrhoeae, C. trachomatis, T. vaginalis and 
M. genitalium was measured using an established multiplex PCR assay at the National 
Institute for Communicable Diseases. The cases of STIs were significantly higher in 
women with inflammation (n=31) for C. trachomatis (19.4%), T. vaginalis (16.1%) or 
any combination of any STI (p=0.0034, p=0.0024 and p=0.0002 respectively) compared 
to women with no inflammation(n=134) (Table 3), suggesting that inflammation is 
strongly associated with STI at the genital tract, and fosters an environment conducive 
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P-value Adjusted P 
value* 
N. gonorrhea 6.5% (n=2) 2.2% (n=3) 0.233 1.165 
C. trachomatis 19.4% (n=6) 3.7% (n=5) 0.0017 0.0085* 
T. vaginalis 16.1% (n=5) 2.2% (n=3) 0.0012 0.006* 
M. genitalium 6.5% (n=2) 12.6% (n=6) 0.0645 0.3225 
Any STI 41.9% (n=13)  12.7% (n=17) 0.0001 0.0005* 
 Women who have STIs and inflammation were compared to women with STIs but 
without inflammation using Chi-square test. P value < 0.05 was significant.  After 
adjustment for multiple comparisons that’s values that retained significance are 
represented by an asterisk (*).  
 
The association between STIs and T cell immune activation status was then investigated 
by comparing the prevalence of STIs among two groups of women: those who had high 
immune and low immune activation status. While more women with STI had high 
levels of CD3+ T cell activation compared to those with low activation (Table 4), this 
was not statistically significant. Although this observation was not statistically 
significant, larger studies have shown that there is an association between the status of 








Table 4. The association between the presence of STIs and T cell immune 
activation status. 
 STI+ Women with high 
immune activation 
STI+ Women with Low 
immune activation 
P value 
CD3 population 23% (n=7/30) 13% (n=4/30) 0.984 
CD4 population 23% (n=7/30) 13% (n=4/30) 0.984 
CD8 population 27% (n=8/30) 12.9% (n=4/35) 0.72 
The level of immune activation was compared in women with STI using Chi-square test. P 
value < 0.05 was significant.   
 
Furthermore, when the relationship between STIs and the frequency of CD4+ immune T 
cells expressing CCR5+ observed at the genital tract was investigated, women who had 
C. trachomatis [p=0.0040, (n=8)], T. vaginalis [p=0.0105, (n=8)] or Any STI 
[p=0.0098, (n=22)] had significantly higher frequencies of CD4+ T cells expressing 
CCR5+ compared to women without STIs. But after adjusting for multiple comparisons, 
there was no significant difference in the frequency of CD4+CCR5+ between women 
infected and none infected with T. vaginalis (p=0.0525). There were no significant 
differences in the frequencies of CD4+CCR5+ T cells between women who had M. 








Table 5. The relationship between STIs and the frequency of CD4+ immune T cells 
expressing CCR5+ 
 CD4+CCR5+ frequency 
in STI+ women 
Median (IQR) 
CD4+CCR5+ 
frequency in STI- 
women  
Median (IQR) 
P value Adjusted 
P value 
N. gonorrohoeae 49.4 (22.8-78.5)  42.5(18.1-65.5)  0.715 3.575 
C. trachomatis  79.3 (47.3-91.8) 39.2 (17.0-63.5) 0.0040 0.020* 
T. vaginalis 70.7 (53.2-85.4)  40.8 (17.6-64.6)  0.0105 0.0525 
M. genitalium 50.5 (9.21-95.8)  42.5 (20.0-65.5)  0.770 3.850 
Any STI 70.7 (35.8-84.8)  43.5 (18.3-66.2)  0.0098 0.049* 
Women with and without STIs were compared using Mann-Whitney test. P value < 0.05 was 
significant.  After adjustment for multiple comparisons the values that retained significance are 
represented by an asterisk (*).  
 
Previous studies have demonstrated that women who had elevated genital inflammatory 
cytokines has a significantly higher risk of HIV acquisition (Masson et al., 2015). In a 
study conducted by Mlisana et al., (2012) the presence of STIs at the genital mucosa 
was both associated with the upregulation of inflammatory cytokine and increased risk 
of HIV acquisition. Furthermore, Smith & Garber (2015), demonstrated the role of STIs 
in cellular recruitment of HIV target cells in mice vaginal tissue. In summary, data in 
this study clearly supports the role of STIs as potential drivers of both immune 
activation and inflammation at the genital tract.  
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CHAPTER 5: DISCUSSION AND CONCLUSION 
Recent studies have demonstrated that increased concentrations of inflammatory 
cytokines and heightened immune T cell activation are among the key components in 
mounting an effective immune response, however in the female genital tract both these 
interconnected physiological processes are known to potentially increase the risk of 
HIV acquisition by up to three times (Masson et al., 2015, Naranbhai et al., 2012). In 
this study, HIV negative women with high T cell immune activation status defined by 
dual expression of CD38+ and HLA-DR had significantly higher frequencies of CD4+ T 
cells expressing CCR5+ and proliferating CD4+ CCR5+ T cells at the genital tract 
compared to women with a low activation status. These data identify women with high 
levels of activation as potentially more at risk for HIV infection by virtue of their 
increased frequencies of activated and replicating targets for HIV infection. In addition, 
based on the definition of inflammation (Masson et al., 2015), some of the women 
studied had genital inflammation (17.5%) while the majority of women had none 
(82.5%). Furthermore, this study also found increased prevalence of C. trachomatis and 
T. vaginalis in women with genital inflammation compared to those without 
inflammation. This suggests that infection with either STI potentially drives 
inflammation in the female genital tract. 
 
Strong evidence has shown that infections elicit an inflammatory response in the genital 
tract, resulting in the upregulation of pro-inflammatory cytokines and the recruitment of 
immune effector cells to site of infection. Univariate analyses do not reflect this, as 
there was no remarkable association observed between individual cytokines and cellular 
markers of immune activation in the genital mucosa. In addition, there were no notable 
observations between women with high and low T cell immune activation status 
attributed to by individual cytokines/chemokines.  
 
Women who had highly activated CD3+ T and CD8+ T cells, had higher concentrations 
of pro-inflammatory cytokines MIF and IL-12p70.Whereas women who had highly 
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activated CD4+ T cells had higher concentration of MIF. IL-12p70 is from the IL-12 
family cytokines, which play a role in inducing the pro-inflammatory responses (Berger, 
2000, Katrina et al., 2009). Counteracting this effect, might have been a high 
concentration of IL-10 that was observed in the genital tract of women with high 
immune activation (CD38+/HLA-DR+: CD3+, CD4+ and CD8+). IL-10 is produced by 
many cell types including dendritic cells, macrophages, B cells, T cells and also by 
innate and regulatory cells (Brooks et al., 2010). The anti-inflammatory cytokine IL-10 
limits the production of pro-inflammatory cytokines among others including IL-1α, IL-
1β, IL-6, IL-18 and TNF α, and also the production of chemokines such as RANTEs, 
MCP-1, IL-8 and MIP (Joss et al., 2000, Couper et al., 2008). 
 
 Interestingly, women with elevated CD38+/HLA-DR+ on CD4+ T cell population had 
higher concentrations of monocyte chemotactic protein 3 (MCP-3).  MCP-3 plays a dual 
role in chemo-attracting and activation of T lymphocytes, monocytes and eosinophils 
among others (Ward et al., 1998). In a study were they investigated the production of 
MCP-3 in an inflamed mucosa, it was observed that MCP-3 is enhanced in regions 
where inflammation is present (Wedemeyer et al., 1999). Though the recruitment of 
immune cells to inflamed areas is imperative for the host defense (Mack et al., 2001). 
CD4+ T cell bear more than one receptor (Zhang et al., 2010), CD4+ T cells recruited by 
MCP-3, may have CCR5+ receptors. As a consequence, this recruitment in the genital 
mucosa may result in inflamed areas rich with HIV target cells. Though the findings in 
this study were not statistically significant, other factors might be potentially blocking 
the effect of individual cytokines on immune activation.  The role of cytokines is 
promiscuous and not limited to T lymphocytes they as they also act on other cell types 
(Ward and Westwick, 1998). 
 
Women who had STIs were mostly found in the group characterized by high immune T 
cell activation status (highly expressing CD38+/HLA-DR+: CD3+, CD4+ and CD8+ 
population) compared to women with low immune T cell activation. Although this 
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observation was not statistically significant, the presence of STIs at the genital tract 
potentially plays a crucial in the activation status and HIV pathogenesis.  
 
Viral entry of HIV into CD4+ T cells is dependent on chemokine co-receptors; 
therefore, expression of CC receptors ultimately influences host susceptibly (Wu et al., 
1996). When comparing the frequencies of potential HIV targets on CD4+ CCR5+ 
bearing T cells in the genital tract between women with STIs and those without STIs, 
the data showed that women who were infected with C. trachomatis, or any 
combination of STIs similarly had significantly higher frequencies of CD4+CCR5+ T 
cells compared to women without STIs in the genital mucosa.  
 
Previous animal studies have shown that high expression of CXCR3+ and CCR5+ by 
CD4+ T cells was associated with clearance of C. trachomatis and that these CXCR3+ 
and CCR5+ chemokine receptors are essential for promoting the recruitment of immune 
cells to resolve the infection (Belay et al., 2002, Olive et al., 2011). Even though in this 
study the number of women who were infected with C. trachomatis was low (6.7%), 
our results are consistent with these findings. Women infected with C. trachomatis had 
significantly higher frequencies of activated CD4+ T cells expressing CCR5+, 
suggesting that homing of CD4+ T cells is essential in C. trachomatis-associated 
immune responses. In a study conducted by (Wu et al., 1997), reduced infectability of 
CD4+ T cells correlated with low CCR5+ expression. Hence, women with high 
frequency of CD4+CCR5+ are more likely to be susceptible.   
 
Based on a postulated mechanism of chlamydial pathogenesis, a response to a 
chlamydial infection is initiated and maintained primarily by the host’s epithelial cells 
(Stephens, 2003). The epithelial lining at the genital mucosa serves as a key innate 
responder by secreting chemokines and cytokines, which results in the influx of immune 
cells and the formation of immune inductive sites in the submucosa (Darville and 
Hiltke, 2010). Among the cells present and abundant at the site of infection are the 
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CD4+ T cells, which serve as targets for HIV infection. As CD4+ T cells seem to play an 
integral role in the resolution of a chlamydial infection in the genital mucosa, it 
coherently increases the chances for the establishment of a successful HIV infection in 
women with a chlamydial infection. 
In this study, it was also observed that infection with T. vaginalis was associated with 
inflammation. However, when the relationship between T. vaginalis and the frequency 
of CD4+ immune T cells expressing CCR5+ observed at the genital tract was 
investigated, data showed that women infected had higher frequencies of CD4+CCR5+ T 
cells at the genital. But after adjustment for multiple comparisons this observation lost 
statistical significance. Immunological responses to T vaginalis infection have been 
studied both in vivo and in vitro (Fichorova, 2009). A study by (Kiviat et al., 1985, 
Fichorova et al., 2006) showed that T. vaginalis infection typically induces local cellular 
immune responses accompanied inflammation in the squamous epithelium in the genital 
tract. thus our results suggest comparable findings.   
 
However, our study did not find significant differences in CD4+ T cells (expressing 
CCR5) and inflammatory status in women who were infected with either N. 
gonorrhoeae or M. genitalium compared to women not infected by any STI. Previous 
studies on M. genitalium have indicated that this pathogen causes inflammation at the 
genital tract (McGowin et al., 2009, McGowin et al., 2013). N. gonorrhea pathogenesis 
also results in the induction of an inflamed local environment through the attachment 
and invasion of epithelial cells at the genital mucosa (McGee et al., 1981). Nonetheless 
colony opacity-associated (Opa) proteins present on the surface of N. gonorrhea are 
known to bind to the carcinoembryonic antigen-related cellular adhesion molecule 
(CEACAM)-1, and the binding of these proteins was accompanied by suppression of 
activation and proliferation of CD4+ T cells (Chen et al., 2001, Boulton and Gray-
Owen, 2002). This explains the suppressed immune activation and the influx of 
CD4+CCR5+ in women infected with N. gonorrhea. The limited evidence to show that 
there was an association between inflammation and STIs was due to a small sample 
size. Furthermore, at the time the study was conducted there was no data on bacterial 
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vaginosis  was not available and study did not look  ulcerative STIs, as both have been 
known to cause immune activation and inflammation.  
 
 
STIs have become a global concern, among other reasons is the role they play in 
facilitating HIV transmission (Sexton et al., 2005, Mlisana et al., 2012, van de Wijgert 
et al., 2009). The genital tract mucosa is the predominant portal of entry for sexually 
transmitted infections. The immune response at this site is essential to provide 
protective aid against invading pathogens that are encountered for the very first time, as 
well as provide long-term secondary immunity necessary to confer resistance against 
STIs. The integrity of the female genital mucosal system is important. While it was 
shown that 99% of unprotected sexual exposure to HIV do not result in a productive 
infection (Royce  et al., 1997), it may be likely that protection against HIV acquisition 
is offered by an intact epithelial barrier, as well as mucosal immune factors present in 
the genital tract. Our data suggest that women with STI will potentially have a genital 
immune milieu characterized by high pro-inflammatory cytokine levels, and high 
frequencies of activated T cells, including CD4+CCR5+ expressing T cell targets for 
HIV replication (Miller & Shattock, 2003; H. Ward & Rönn, 2010). Taken together, 
STI can promote an immune environment conducive to HIV replication. 
 
The high HIV incidence rate in young women (UNAIDS, 2016) can be partially 
explained by behavioral risks. In a health-care system where there is a syndromic 
management of STIs, the impact of STIs, especially asymptomatic infections on CD4+ T 
cell activation and inflammation in the genital mucosa needs to be urgently addressed. 
A recent study has shown that there is a high prevalence and incidence of reported STIs 
among women in rural and urban areas in KwaZulu-Natal, South Africa (Abbai et al., 
2013). To alleviate STIs/HIV burden especially on women understanding intricacies of 
STI pathogenesis and its role in HIV transmission, is vital to curb the HIV pandemic. 
As much as it is economical in resource poor countries to effectively manage infectious 
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diseases, which involves diagnosis, prevention and treatment (Ronald et al., 2006), new 
interventions are required to be established. 
 
In conclusion, our findings suggest discharge-associated STIs in CAPRISA 008 study 
participants play a role in recruitment of HIV target cells, are potential drivers of 
inflammation in the genital tract, and may foster an environment conductive to HIV 
acquisition.  In developing countries, the incidence and prevalence of STI rates are 
generally high and impose a health burden. This is a result of a variety of factors 
amongst others include poor health service provision and expensive cost of setting up 
good quality STI services is costly in resource poor settings. Under these prevailing 
conditions, it is still critical to find measures to curb STI infections by providing 
medical interventions for those who are currently infected. These data support the 
concept of reducing HIV risk by limiting STI-associated inflammation and recruitment 
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Figure 3.1 Representative plots showing the gating strategy used to define activated T-cell populations by flow cytometry. 
Peripheral blood mononuclear cells were stained with fluorochrome labeled monoclonal antibodies CD3 (APC-H7), CD4 (PerCP. Cy5.5), 
CD8 (FITC), CCR5 (APC), Ki67 (BV 700), HLA-DR (PE) and CD14/CD19/Live/Dead stain Fixable Violet Dead Cell Stain (Pacific Blue). A 
singlet gate was used to exclude cell doublets or cell aggregates. Live CD3+ T cell population was divided into CD4+ and CD8+ subsets. 
The overall expression of activation markers on CD3+, CD4+ and CD8+ was evaluated. Fluorescence minus one (FMO) were used to 
determine the positioning of the specific gates.  
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Table 3.3.2 A: Shows the cytokine/chemokine expression profiles between women 




High immune activation (n=30) 
Median (IQR) 





IL-1α 2.44 (2.04-2.66) 2.17 (1.93-2.46) 0.157 
IL-1β 1.9 (1.41-2.25) 1.61 (0.972-2.2) 0.270 
IL-6 1.01 (0.861-1.32) 1.01 (0.599-1.44) 0.6182 
IL-12p40 2.56 (2.42-2.74) 2.54(2.33-2.79) 0.761 
IL-18 2.5 (1.98-2.81) 2.51 (2.23-2.67) 0.766 
MIF 3.86 (3.63-4.44) 3.65 (3.27-3.950 0.0217 
TNF-α 1.23 (1.08-1.46) 1.07 (0.93-1.45) 0.0905 
TNF-β 0.713 (0.468-0.884) 0.841 (0.543-1.16) 0.0822 
TRAIL 1.81 (1.6-2.2) 1.82 (1.37-2.23) 0.99 
IL-12p70 1.65 (1.46-1.86) 1.49 (1.23-1.66) 0.0173 
Chemokines 
CTACK 1.53(1.27-1.68) 1.53(1.21-1.72) 0.826 
Eotaxin 0.436 (0.0811-1.16) 0.174 (0.0881-1.29) 0.834 
GRO-α 2.84 (2.44-4.72) 3.07 (2.37-3.92) 0.817 
IL-8 2.73 (2.44-3.23) 2.72 (2.35-3.240) 0.7986 
IL-16 1.86 (1.63 -1.95) 1.7 (1.47-2.1) 0.199 
IP-10 2.39 (1.93-3.25) 2.76 (2.06-3.160 0.5202 
MCP-1 1.46 (1.34-1.580 1.28 (1.19-1.4) 0.0024 
MIP-1α 0.5 (0.43-0.615) 0.534 (0.427-0.647) 0.4932 
MIP-1β 1.13 (0.915-1.52) 1.26 (0.806-1.66) 0.756 
MIG 2.99 (2.54-3.73) 2.78 (2.15-3.37) 0.162 
RANTES 1.32 (1.1-1.74) 1.18 (1.11-1.41) 0.257 
INF-α2 1.42 (1.18-1.510 1.42 (1.18-1.6) 0.832 
Growth factors 
Basic FGF 1.43 (1.23-1.52) 1.38 (1.23-1.52) 0.131 
G-CSF 2.41 (2.22-2.41) 2.45 (1.84-3) 0.732 
GM-CSF 2.33 (2.27-2.42) 2.42 (2.29-2.46) 0.092 
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HGF 2.41 (2.09-2.78) 2.28 (1.73-2.77) 0.352 
IL-3 2.23 (2.02-2.35) 2.3 (2.05-2.51) 0.223 
IL-7  0.663 (0.605-0.824) 0.592 (0.453-0.958) 0.4532 
IL-9 0.886 (0.788-1.04) 0.861 (0.636-1.02) 0.194 
LIF 1.39 (1.14-1.47) 1.18 (0.978-1.42) 0.269 
M-CSF 2.04 (1.83-2.36) 2.32 (2.04-2.53) 0.0144 
PDGF-bb 1.21 (1.07-1.43) 1.28 (1.06-1.55) 0.8381 
SCF 1.14 (0.876-1.35) 1.22 ( 0.869-1.54) 0.5221 
SCGF-β 2.71 (2.38-2.99) 2.94 (2.49-3.53) 0.120 
SDF-1α 2.1 (1.92-2.21) 2.0 (1.75-2.18) 0.197 
VEGF 2.71 (2.51-2.96) 2.62 (2.37-2.98) 0.549 
b-NGF 1.45 (1.18-1.510 1.47 (1.18-1.6) 0.832 
Adaptive cytokines 
IFN-γ 1.53 (1.45-1.8) 1.71 (1.44-1.98) 0.223 
IL-2 0.751 (0.21-0.895) 0.251 (0.0086-0.896) 0.1725 
IL-4 0.299 (0.237-0.415) 0.294 (0.225-0.413) 0.675 
IL-5 0.217 (0.166-0.323) 0.17 (0.0314-0.284) 0.119 
IL-13 0.647 (0.528-0.818) 0.535 (0.362-0.761) 0.109 
IL-15 0.647 (0.528-0.818) 0.535 (0.362-0.761) 0.109 
IL-17 0.0128 (0.0128- 0.0128) 0.0128 (0.0128- 0.739) 0.0388 
IL2Rα 1.65 (1.38-1.81) 1.58 (1.34-1.84) 0.674 
Anti-inflammatory cytokines 
IL-10 1.45 (1.39-1.56) 1.32 (1.21-1.46) 0.0064 
IL-1Rα 3.99 (3.9-4.16) 4.05 (3.82-4.15) 0.755 
The log concentrations of cytokine/chemokine expression profiles in women with low 
and high which were compared using Mann-Whitney test, an asterisk (*) represents P 
values ≤ 0.05.  
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Table 3.3. 2B: Shows the cytokine/chemokine expression profiles between women 
with low and high T cell immune activation status in CD4+ population. 
 
Individual cytokine High immune activation 
(n=30) 




IL-1α 2.21 (1.94-2.62) 2.17 (1.94-2.36) 0.387 
IL-1β 1.69 (1.31-2.34) 1.63 (0.958-2.07) 0.270 
IL-6 1.01 (0.833-1.21) 0.991 (0.626-1.23) 0.655 
IL-12p40 2.52 (2.42-2.66) 2.54 (2.22-2.65) 0.517 
IL-18 2.5 (2.09-2.85) 2.51 (2.24-2.680) 0.924 
MIF 3.83 (3.65-4.35) 3.68 (3.25-3.96) 0.0235* 
TNF-α 1.21 (1.09-1.36) 1.13 (0.924-1.40) 0.134 
TNF-β 0.675 (0.426-0.844) 0.708 (0.539-1.08) 0.173 
TRAIL 1.83 (1.6-2.2) 1.7 (1.28-2.04) 0.210 
IL12p70 1.61 (1.31-1.82) 1.48 (1.26-1.62) 0.219 
Chemokines 
CTACK 1.45 (1.27-1.69) 1.53 1.16-1.75) 0.793 
Eotaxin 0.59 (0.0881-1.17) 0.0881 (0.0881-1.30) 0.587 
GRO-α 2.82 (2.55-4.87) 3.01 (2.79-3.82) 0.751 
IL-8 2.66 (2.43-3.13) 2.64 (2.19-3.26) 0.728 
IL-16 1.82 (1.63-1.91) 1.7 (1.42-2.07) 0.878 
IP-10 2.30 (2.00-3.11) 2.76 (2.34-3.42) 0.520 
MCP-1 1.39 (1.31-1.56) 1.32 (1.22-1.54) 0.119 
MIP-1α 0.514 (0.431-0.626) 0.504 (0.395-0.647) 0.858 
MIP-1β 1.15 (1.02-1.50) 1.271 (0.950-1.73) 0.405 
MIG 2.99 (2.47-3.53) 2.82 (2.51-3.290) 0.741 
RANTES 1.27 (1.10-1.60) 1.16  (1.08-1.41) 0.346 
IFN-α2 1.4 (1.18-1.51) 1.42 (1.13-1.56)  0.924 
MCP-3 1.17 (1.0-1.3) 1.01 (-0.177-1.27) 0.0180* 
Growth factors 
Basic FGF 1.42 (1.36-1.61) 1.37 (1.23-1.51) 0.0491* 
G-CSF 2.34 (2.04-2.73) 2.38 (1.98-3.04) 0.735 
GM-CSF 2.34 (2.28-2.42) 2.41 (2.30-2.46) 0.236 
HGF 2.28 (1.94-2.73) 2.28 (1.86-2.74) 0.619 
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IL-3 2.19 (2.01-2.33)  2.3 (2.00-2.44) 0.368 
IL-7  0.67 (0.599-0.828) 0.547 (0.455-0.852) 0.162 
IL-9 0.889 (0.798-0.988) 0.887 (0.634-1.02) 0.223 
LIF 1.18 (1.04-1.45) 1.18 (1.01-1.4) 0.444 
M-CSF 1.97 (1.82-2.21) 2.32 (2.03-2.51) 0.0248* 
PDGF-bb 1.255 (1.07-1.42) 1.26 (0.927-1.46) 0.748 
SCF 1.09(0.874-1.3) 1.22 (0.881-1.53) 0.269 
SCGF-β 2.72 (2.33-3.07) 2.94 (2.32-3.22) 0.425 
SDF-1α 2.04 (1.92-2.19)  2.01 (1.8-2.16) 0.226 
VEGF 2.649 (2.393-2.948) 2.64 (2.56-3.05) 0.584 
b-NGF 2.0 (1.75-2.18) 2.23 (2.02-2.35) 0.0491* 
Adaptive cytokines 
IFN-γ 1.51 (1.45-1.78) 1.62 (1.44-2.03) 0.326 
IL-2 0.706 (0.279-0.879) 0.117 (0.0086-0.856) 0.101 
IL-4 0.2956 (0.245-0.393) 0.288 (0.206-0.387) 0.396 
IL-5 0.203 (0.147-0.327) 0.173 (0.0492-0.218) 0.131 
IL-13 0.666(0.525-0.858) 0.513 (0.378-0.739) 0.0468* 
IL-15 0.0128 (0.0128-0.240) 0.0128 (0.0128-0.435) 0.454 
IL-17 1.37 (1.25-1.48) 1.27 (0.919-1.43) 0.117 
IL2Rα 1.56 (1.39-1.72) 1.6 (1.32-1.83) 0.838 
Anti-inflammatory cytokines 
IL-10 1.44 (1.39-1.56) 1.32 (1.20-1.44) 0.0059* 
IL-1Rα 4.01 (3.90-4.22) 3.99 (3.8 -4.14) 0.198 
The log concentrations of cytokine/chemokine expression profiles in women with low 
and high which were compared using Mann-Whitney test, an asterisk (*) represents P 
values ≤ 0.05.
 50 
Table 3.3.2 C: Shows the cytokine/chemokine expression profiles between women 
with low and high T cell immune activation status in CD8 population. 
 
Individual cytokine High immune activation 
(n=30) 




IL-1α 2.39 (2.04-2.64) 2.1 (1.78-2.37)  0.0514 
IL-1β 1.9 (1.5-2.27) 1.58 (0.788-2.02) 0.270 
IL-6 0.963 (0.827-1.29) 0.962 (0.591-1.35) 0.777 
IL-12p40 2.52 (2.42-2.72) 2.53 (2.23-2.73)  0.417 
IL-18 2.49 (1.98-2.73)  2.48 (2.22-2.67)  0.878 
MIF 3.82 (3.62-4.07)  3.51 (3.22-3.86) 0.0056* 
TNF-α 1.23 (1.08-1.46) 1.15 (0.975-1.39) 0.198 
TNF-β 0.641 (0.468-0.862) 0.843 (0.522-1.16) 0.133 
TRAIL 1.81 (1.48-2.2) 1.86 (1.38-2.25) 0.913 
IL12p70 1.65 (1.49-1.84) 1.48 (1.16-1.67) 0.0102* 
Chemokines 
CTACK 1.47 (1.27-1.64) 1.48 (1.26-1.75) 0.997 
Eotaxin 0.575 (0.0881-1.16) 0.925 (0.0881-1.3) 0.475 
GRO-α 2.8 (2.44-4.62)  3.06 (2.6-4.05)  0.835 
IL-8 2.73 (2.37-3.23) 2.62 (2.19-3.13) 0.468 
IL-16 1.8 (1.61-1.92)  1.7 (1.54-2.04) 0.944 
IP-10 2.29 (1.65-3.25) 2.75 (1.92-3.13) 0.564 
MCP-1 1.38 (1.32-1.62) 1.31 (1.21-1.46) 0.0326 
MIP-1α 0.5 (0.436-0.615) 0.526 (0.427-0.629) 0.831 
MIP-1β 1.14 (0.915-1.52) 1.21 (0.788-1.65) 0.771 
MIG 2.98 (2.5-3.52) 2.75 (2.15-3.24) 0.127 
RANTES 1.32 (1.12-1.63) 1.21 (1.11-1.4) 0.229 
INF-α2 1.39 (1.18-1.5) 1.41 (1.17-1.62) 0.917 
MCP-3 1.18 (0.997-1.31) 1.11 (-0.177-1.31) 0.210 
Growth factors 
Basic FGF 1.43(1.37-1.6)  1.38 (1.29-1.5)  0.0992 
G-CSF 2.35 (2.08-2.88) 2.42 (1.69-2.96) 0.921 
GM-CSF 2.34 (2.28-2.42) 2.38 (2.22-2.46) 0.578 
HGF 2.3 (1.98-2.75)  2.22 (1.75-2.76) 0.353 
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IL-3 2.16 (2-2.35) 2.28 (2-2.51) 0.345 
IL-7  0.663 (0.612-0.803) 0.597 (0.415-0.969) 0.644 
IL-9 0.891 (0.807-1.04) 0.911 (0.66-1.02) 0.205 
LIF 1.2 (1.14-1.49) 1.17 (0.944-1.38) 0.102 
M-CSF 2.03 (1.83-2.36) 2.26 (2.01-2.59) 0.0229* 
PDGF-bb 1.21 (1.07-1.4) 1.14 (0.927-1.45) 0.906 
SCF 1.1 (0.861-1.34) 1.16 (0.844-1.47) 0.782 
SCGF-β 2.7 (2.28-2.98) 2.84 (2.43-3.29) 0.179 
SDF-1α 2.04 (1.92-2.19) 1.98 (1.83-2.17) 0.182 
VEGF 2.71 (2.52-2.96) 2.57 (2.32-2.95) 0.331 
b-NGF 2.43(1.37-2.6)  1.98 (1.29-2.02)  0.0186* 
Adaptive cytokines 
IFN-γ 1.53 (1.45-1.8) 1.59 (1.25-1.97) 0.521 
IL-2 0.751 (0.21-0.897) 0.504 (0.0086-0.856) 0.227 
IL-4 0.299 (0.237-0.415) 0.297 (0.22-0.387) 0.750 
IL-5 0.225 (0.185-0.33) 0.104 (0.0107-0.217) 0.0014* 
IL-13 0.647 (0.528-0.819) 0.556 (0.34-0.76) 0.147 
IL-15 0.0128 (0.0128-0.177) 0.0128 (0.012-0.943) 0.0323 
IL-17 1.36 (1.25-1.48) 1.32 (1.24-1.43) 0.598 
IL2Rα 1.6 (1.38-1.81) 1.59 (1.32-1.83) 0.559 
Anti-inflammatory cytokines 
IL-10 1.45 (1.39-1.55) 1.33 (1.25-1.44) 0.0138* 
IL-1Rα 4.01 (3.91-4.16) 4.01 (3.75-4.13) 0.383 
The log concentrations of cytokine/chemokine expression profiles in women with low 
and high which were compared using Mann-Whitney test, an asterisk (*) represents P 
values ≤ 0.05.  
 52 
Table 3.3 A: The frequency of cellular markers compared between women who 
have inflammation and women that do not have inflammation. 
 





Live CD3 T cells 12.8 (6.24-20.7) 11.1 (5.42-22.8) 0.664 
CD3+ CCR5+ 29.0 (14.8-63.2) 35.3 (19.0-59.1) 0.592 
CD3+ CD38+ 23.4 (3.12-48) 19 (4.69-64.7) 0.408 
CD3+ HLA-DR+ 8.71 (3.75-16) 7.33 (4.56-15.4) 0.883 
CD3+ Ki67+ 27.5 (0.217-40) 32 (0.385-49.5) 0.818 
CD3+ CD38+/HLA-DR+ 2.66 (0.326-8.12) 2.43 (0.632-9.68) 0.804 
CD3+ CCR5+/CD38+/HLA-
DR+ 
1.67 (0.129-5.66) 1.02 (0.244-5.31) 0.957 
CD3+ Total activation 57.6 (34.7-80.5) 62.6 (45.4-89) 0.370 
CD4 +T cells 46.7 (25.7-60.6) 45 (34.5-54.7) 0.912 
CD4+ CCR5+ 29 (12.4-68.1) 39.4 (14.9-60) 0.613 
CD4+ CD38+ 16.1 (1.26-55.2) 14.6 (1.5-77) 0.730 
CD4+ HLA-DR+ 16.3 (11.6-22.8) 14.1 (6.2-31.6) 0.654 
CD4+ Ki67+ 37.5 (0.25-51.5) 31.3 (0.236-51.4) 0.612 
CD4+ CD38+/HLA-DR+ 4.05 (0.31-12) 2.41 (0.51-18) 0.978 
CD4+ CCR5+/CD38+/HLA-
DR+ 
2.15 (0.095-8.69) 0.71 (0-8.48) 0.423 
CD4+ Total activation 59.7 (31.6-94.1) 66.9 (47.1-96.5) 0.412 
 CD8+ T cells 20.6 (14.3-27.5) 28 (16-38.1) 0.093 
CD8+ CCR5+ 36.4 (10.6-60.1) 33 (17.6-56) 0.787 
CD8 CD38 18.4 (0.526-72.5) 17.4 (1.11-75.2) 0.730 
CD8+ HLA-DR+ 8.04 (6.18-25.8) 10.3 (4.29-21.4) 0.898 
CD8+ ki67+ 43.7 (0.035-50.2) 42.4 (0-72.1) 0.692 
CD8+ CD38+/HLA-DR+ 3.71 (0.0217-8.23) 13 (0-13.2) 0.842 
CD8+ CCR5+/CD38+/HLA-
DR+ 
1.35 (0-5.59) 0.494 (0-7.66) 0.929 
CD8+ Total activation 63 (34.9-93.7) 75.6 (47-95.1) 0.442 
  
 53 
Table 3.3B: The event count of cellular markers compared between women who 
have inflammation and women that do not have inflammation. 





Live CD3 T cells 1008 (475-2641) 909 (346-1584) 0.201 
Live CD3 T cells 241 (82-611) 290 (95-688) 0.932 
CD3+ CCR5+ 129 (40-457) 118 (46.5-557) 0.992 
CD3+ CD38+ 88 (41-266) 68 (24-164) 0.385 
CD3+ HLA-DR+ 197 (3-356) 146 (3-529) 0.905 
CD3+ Ki67+ 24 (11-111) 17 (5-77) 0.566 
CD3+ CD38+/HLA-DR+ 14 (3-80) 10 (2-46) 0.957 
CD3+ CCR5+/CD38+/HLA-DR+ 461 (229-1172) 580 (197-1040) 0.809 
CD3+ Total activation 312 (203-783) 377 (130-682) 0.644 
CD4 CCR5 112 (30-153) 109 (39-303) 0.259 
CD4 +T cells 110 (10-200) 95 (175-315) 0.465 
CD4+ CCR5+ 48 (31-112) 49 (17.8-148) 0.809 
CD4+ CD38+ 74 (2-149) 63 (2-247) 0.476 
CD4+ HLA-DR+ 11 (2-48) 12 (1-57 0.632 
CD4+ Ki67+ 3 (1-29) 4 (0-24) 0.965 
CD4+ CD38+/HLA-DR+ 224 (108-291) 208 (74-463) 0.806 
CD4+ CCR5+/CD38+/HLA-DR+ 177 (69-547) 184 (71-507) 0.977 
CD8+ CCR5 30 912-95) 67 (16-222) 0.355 
CD8+ CD38+ 19 (3-76) 15 (4-107) 0.771 
CD8+ HLA-DR+ 14 (6-99) 18 (5-50) 0.713 
CD8+ ki67+ 28 (0-90) 53 (0-238) 0.375 
CD8+ CD38+/HLA-DR+ 3 (0-21) 3 (0-17) 0.830 
CD8+ CCR5+/CD38+/HLA-DR+ 1 (0-21) 1 (0-10) 0.788 
CD8+ Total activation 89 (28-147) 89 (29-374) 0.523 
Sum of CD4+ and CD8+ T cells 518 (272-1669) 649 (242-1157) 0.548 
CD4+/CD8+ ratio 2.53 (1.51-2.92) 1.76 (1.09-2.67) 0.203 
Cellular markers in women with inflammation (n=20) were compared to those with 
women who had no inflammation (n=94) using Mann-Whitney test.   
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